Faculty & Disclosures
Dr Stephen Graves
Division of Nuclear Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Dr Graves is a medical physicist, certified by the American Board of Radiology in both nuclear medicine physics and radiation oncology physics, with extensive experience in radiopharmaceutical therapy (RPT), quantitative nuclear imaging, radiation dosimetry and nuclear metrology. read more
His research has focused on development of new medical radioisotopes for imaging and translation of new radiopharmaceutical agents into the clinic. Dr Graves is the primary medical physicist supporting clinical needs of the University of Iowa Comprehensive Radiopharmaceutical Therapy Center of Excellence, USA.
Dr Graves is internationally recognized for his expertise in RPT dosimetry, including nuclear detection and measurement, single photon imaging and optimal clinical use of approved therapies.
Dr Stephen Graves discloses: Advisory board or panel fees from Isotope Technologies Munich, Novartis and Voximetry. Consultancy fees from CDE Dosimetry Services and RayzeBio. Grants/research support from Siemens. Other financial or material support (royalties, patent, etc.) from Wisconsin Alumni Research Foundation.
Dr Ana Kiess
Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Ana Kiess is associate professor and residency program director in the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University, USA. read more
Her research focuses on new radiopharmaceutical agents, combination therapies, radiopharmaceutical therapy (RPT) dosimetry and toxicities. Her clinical practice includes radiopharmaceutical agents for prostate cancer and other cancers, and she is active in multiple RPT education initiatives.
Dr Ana Kiess discloses: Advisory board or panel fees from Novartis (relationship terminated) Consultancy fees from Novartis (relationship terminated). Grants/research support from Bayer, Merck and Novartis. Speaker’s bureau fees from POINT Biopharma (relationship terminated).
Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
